Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014 (2014), Article ID 719175, 12 pages
http://dx.doi.org/10.1155/2014/719175
Clinical Study

Postmastectomy Radiotherapy for Locally Advanced Breast Cancer Receiving Neoadjuvant Chemotherapy

1Department of Radiation-Oncology, University of Florence, Largo G. A. Brambilla 3, 50134 Florence, Italy
2Molecular and Nutritional Epidemiology Unit, ISPO (Cancer Research and Prevention Institute), University of Florence, Largo G. A. Brambilla 3, 50134 Florence, Italy
3Diagnostic Senology Unit, University of Florence, Largo G. A. Brambilla 3, 50134 Florence, Italy
4Department of Surgery, University of Florence, Largo G. A. Brambilla 3, 50134 Florence, Italy
5Department of Gynecology and Obstetrics, University of Florence, Largo G. A. Brambilla 3, 50134 Florence, Italy
6Department of Pathology, University of Florence, Largo G. A. Brambilla 3, 50134 Florence, Italy

Received 27 February 2014; Revised 7 May 2014; Accepted 21 May 2014; Published 22 June 2014

Academic Editor: An Liu

Copyright © 2014 Icro Meattini et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Neoadjuvant chemotherapy (NAC) is widely used in locally advanced breast cancer (BC) treatment. The role of postmastectomy radiotherapy (PMRT) after NAC is strongly debated. The aim of our analysis was to identify major prognostic factors in a single-center series, with emphasis on PMRT. From 1997 to 2011, 170 patients were treated with NAC and mastectomy at our center; 98 cases (57.6%) underwent PMRT and 72 cases (42.4%) did not receive radiation. At a median follow-up period of 7.7 years (range 2–16) for the whole cohort, median time to locoregional recurrence (LRR) was 3.3 years (range 0.7–12.4). The 5-year and 10-year actuarial LRR rate were 14.5% and 15.9%, respectively. At the multivariate analysis the factors that significantly correlated with survival outcome were ≥4 positive nodes (HR 5.0, 1.51–16.52; ), extracapsular extension (HR 2.18, 1.37–3.46; ), and estrogen receptor positive disease (HR 0.57, 0.36–0.90; ). Concerning LRR according to use of radiation, PMRT reduced LRR for patient with clinical T3 staged disease ( ). Our experience confirmed the impact of pathological nodal involvement on survival outcome. PMRT was found to improve local control in patients presenting with clinical T3 tumors, regardless of the response to chemotherapy.